MACVIA clinical decision algorithm in adolescents and adults with allergic rhinitis by Bousquet, J et al.
MACVIA clinical decision algorithm in adolescents
and adults with allergic rhinitisJean Bousquet, MD,a,b,c Holger J. Sch€unemann, MD,d Peter W. Hellings, MD,e Sylvie Arnavielhe, PhD,f
Claus Bachert, MD,g Anna Bedbrook, BSc,b Karl-Christian Bergmann, MD,h Sinthia Bosnic-Anticevich, PhD,i
Jan Brozek, MD,d Moises Calderon, MD,j G. Walter Canonica, MD,k Thomas B. Casale, MD,l Niels H. Chavannes, MD,m
Linda Cox, MD,n Henry Chrystyn, PhD,o Alvaro A. Cruz, MD,p Ronald Dahl, MD,q Giuseppe De Carlo, MD,r
Pascal Demoly, MD,s,t Phillipe Devillier, MD,u Gerard Dray, PhD,v Monica Fletcher, MSc,w Wytske J. Fokkens, MD,x
Joao Fonseca, MD,y Sandra N. Gonzalez-Diaz, MD,z Lawrence Grouse, MD,aa Thomas Keil, MD,bb Piotr Kuna, MD,cc
Desiree Larenas-Linnemann, MD,dd Karin C. Lodrup Carlsen, MD,ee Eli O. Meltzer, MD,ff Jaoquim Mullol, MD,gg
Antonella Muraro, MD,hh Robert N. Naclerio, MD,ii Susanna Palkonen, MD,r Nikolaos G. Papadopoulos, MD,jj
Giovanni Passalacqua, MD,k David Price, MD,kk Dermot Ryan, MD,ll Boleslaw Samolinski, MD,mm
Glenis K. Scadding, MD,nn Aziz Sheikh, MD,oo Franc¸ois Spertini, MD,pp Arunas Valiulis, MD,qq Erkka Valovirta, MD,rr
Samantha Walker, PhD,ss Magnus Wickman, MD,tt Arzu Yorgancioglu, MD,uu Tari Haahtela, MD,vv and
Torsten Zuberbier, MD,h on behalf of the MASK study group* Montpellier, Paris, St-Quentin-en-Yvelines, and Ales, France;
Hamilton, Ontario, Canada; Leuven, Ghent, and Brussels, Belgium; Berlin and Wuerzberg, Germany; Glebe, Australia; London, Cambridge,
Warwick, Manchester, Aberdeen, and Edinburgh, United Kingdom; Genoa and Padua, Italy; Tampa and Davie, Fla; Bahia, Brazil; Leiden and
Amsterdam, The Netherlands; Odense, Denmark; Porto, Portugal; Nuevo Leon and Mexico City, Mexico; Seattle, Wash; Lodz and Warsaw,
Poland; Oslo, Norway; San Diego, Calif; Barcelona, Spain; Chicago, Ill; Athens, Greece; Vilnius, Lithuania; Turku, Finland; Stockholm,
Sweden; Manisa, Turkey; and Lausanne, SwitzerlandThe selection of pharmacotherapy for patients with allergic
rhinitis (AR) depends on several factors, including age,
prominent symptoms, symptom severity, control of AR, patient
preferences, and cost. Allergen exposure and the resulting
symptoms vary, and treatment adjustment is required. ClinicalFrom aUniversity Hospital, Montpellier; bMACVIA-LR, Contre les MAladies Chroni-
ques pour un VIeillissement Actif en Languedoc-Roussillon, European Innovation
Partnership on Active and Healthy Ageing Reference Site, Montpellier; cINSERM,
VIMA: Ageing and Chronic Diseases, Epidemiological and Public Health approaches,
Paris, and Universite Versailles St-Quentin-en-Yvelines; dthe Departments of Clinical
Epidemiology and Biostatistics and Medicine, McMaster University, Hamilton; ethe
Laboratory of Clinical Immunology, Department of Microbiology and Immunology,
KU Leuven; fKyomed, Montpellier; gthe Upper Airways Research Laboratory, ENT
Department, Ghent University Hospital; hAllergy-Centre-Charite at the Department
of Dermatology, Charite–Universit€atsmedizin Berlin, and Secretary General of the
Global Allergy and Asthma European Network (GA2LEN); ithe Woolcock Institute
of Medical Research, University of Sydney and Sydney Local Health District, Glebe;
jImperial College London–National Heart and Lung Institute, Royal Brompton Hospi-
tal NHS, London; kthe Allergy and Respiratory Diseases Clinic, DIMI, University of
Genoa, IRCCS AOU San Martino-IST, Genoa; lthe Division of Allergy/Immunology,
University of South Florida, Tampa; mthe Department of Public Health and Primary
Care, Leiden University Medical Center; nthe Department of Medicine, Nova South-
eastern University, Davie; oRiRL, Cambridge; pProAR–Nucleo de Excelencia em
Asma, Federal University of Bahia, and GARD Executive Committee; qthe Depart-
ment of Dermatology and Allergy Centre, Odense University Hospital, Odense;
rEFA European Federation of Allergy and Airways Diseases Patients’ Associations,
Brussels; sEPAR U707 INSERM, Paris and EPAR UMR-S UPMC, Paris VI, Paris;
tthe Department of Respiratory Diseases, Montpellier University Hospital; uLabora-
toire de Pharmacologie Respiratoire UPRES EA220, Ho^pital Foch, Suresnes Uni-
versite Versailles Saint-Quentin; vEcole des Mines, Ales; wEducation for Health,
Warwick; xthe Department of Otorhinolaryngology, Academic Medical Centre, Am-
sterdam; ythe Center for Research in Health Technologies and Information Sys-
tems–CINTESIS, Universidade do Porto; the Allergy Unit, Instituto CUF Porto e
Hospital CUF Porto; the Health Information and Decision Sciences Department–
CIDES, Faculdade de Medicina, Universidade do Porto; Faculdade de Medicina da
Universidade do Porto, Porto; zUniversidad Autonoma de Nuevo Leon; aathedecision support systems (CDSSs) might be beneficial for the
assessment of disease control. CDSSs should be based on the
best evidence and algorithms to aid patients and health care
professionals to jointly determine treatment and its step-up or
step-down strategy depending on AR control. Contre lesUniversity of Washington School of Medicine, Faculty of the Department of
Neurology, Seattle; bbthe Institute of Social Medicine, Epidemiology and Health Eco-
nomics, Charite–Universit€atsmedizin Berlin, and the Institute for Clinical Epidemi-
ology and Biometry, University of Wuerzburg; ccthe Division of Internal Medicine,
Asthma and Allergy, Barlicki University Hospital, Medical University of Lodz;
ddClınica de Alergia, Asma y Pediatrıa, Hospital Medica Sur, Mexico City; eethe
Department of Paediatrics, Oslo University Hospital, Oslo, and the Faculty of Medi-
cine, Institute of ClinicalMedicine, University of Oslo; ffthe Allergy andAsthmaMed-
ical Group and Research Center, San Diego; ggUnitat de Rinologia i Clınica de
l’Olfacte, Servei d’ORL, Hospital Clınic, Clinical & Experimental Respiratory Immu-
noallergy, IDIBAPS, Barcelona; hhFood Allergy Referral Centre Veneto Region,
Department ofWomen and ChildHealth, PaduaGeneral University Hospital; iithe Sec-
tion of Otolaryngology-Head and Neck Surgery, University of Chicago Medical Cen-
ter and Pritzker School of Medicine, University of Chicago; jjthe Center for Pediatrics
and Child Health, Institute of Human Development, Royal Manchester Children’s
Hospital, University of Manchester, and the Allergy Department, 2nd Pediatric Clinic,
Athens General Children’s Hospital ‘‘P&AKyriakou,’’ University of Athens; kkthe Ac-
ademic Centre of Primary Care, University of Aberdeen, and Research in Real-Life,
Cambridge; llHonorary Clinical Research Fellow, Allergy and Respiratory Research
Group, University of Edinburgh; mmthe Department of Prevention of Envinronmental
Hazards and Allergology, Medical University of Warsaw; nnRoyal National TNE Hos-
pital, University College London; oothe Allergy and Respiratory Research Group,
Centre for Population Health Sciences, University of Edinburgh; ppService d’Immuno-
logie et Allergie, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne; qqVil-
nius University Clinic of Children’s Diseases, Vilnius; rrthe Department of Lung
Diseases and Clinical Allergology, University of Turku; ssAsthma UK, London;
ttSachs’ Children’s Hospital, Stockholm, and the Institute of Environmental Medicine,
Karolinska Institutet, Stockholm; uuthe Department of Pulmonology, Celal Bayar Uni-
versity Manisa, Turkey, and GARD Executive Committee; and vvSkin and Allergy
Hospital, Helsinki University Hospital, Helsinki.
367
Abbreviations used
AR: Allergic rhinitis
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MACVIA-LR: Contre les MAladies Chroniques pour un VIeillisse-
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MASK: MACVIA-ARIA Sentinel Network
MCID: Minimal clinically important difference
QOL: Quality of life
RQLQ: Rhinoconjunctivitis Quality of Life Questionnaire
VAS: Visual analog scale
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Languedoc-Roussillon (MACVIA-LR [fighting chronic diseases
for active and healthy ageing]), one of the reference sites of the
European Innovation Partnership on Active and Healthy
Ageing, has initiated an allergy sentinel network (the MACVIA-
ARIA Sentinel Network). A CDSS is currently being developed
to optimize AR control. An algorithm developed by consensus is
presented in this article. This algorithm should be confirmed by
appropriate trials. (J Allergy Clin Immunol 2016;138:367-74.)
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The selection of pharmacotherapy for patients with allergic
rhinitis (AR) depends on several factors, such as age, prominent
symptoms, symptom severity, control of AR, patient preferences,
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or step-down strategy depending on AR control.1 Thus CDSSs
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Box 1. Summary of recommendations for the treatment of AR and conjunctivitis used in the algorithm
d Oral or intranasal H1-antihistamines are less effective than intranasal corticosteroids for the control of all rhinitis symptoms.
28-33
d Leukotriene receptor antagonists are usually considered less effective than oral H1-antihistamines.
30,34,35
d Comparisons between oral and intranasal H1-antihistamines differ between recommendations, and thus no definite conclu-
sions have yet been reached.
d Combined intranasal fluticasone propionate and azelastine hydrochloride in a single device is more effective than monotherapy
and is indicated for patients when monotherapy with either an intranasal H1-antihistamine or glucocorticoid is considered
inadequate.1,34-37
d Intranasal antihistamines and intranasal corticosteroids are effective for ocular symptoms, with no significant difference be-
tween them.38,39 However, the combination of azelastine and fluticasone propionate was more effective than fluticasone pro-
pionate alone.36,37
d In most studies, combinations of oral antihistamines or leukotriene receptor antagonists and intranasal corticosteroids are in
general not more effective than monotherapy with intranasal corticosteroids.40,41
d Intraocular H1-antihistamines or cromones are effective for ocular symptoms.
42 The importance of decongestants is debat-
able.30 However, the efficacy of treatment varies with individual patient response.
d In clinical practice, intranasal corticosteroids need a few days to be fully effective, whereas intranasal H1-antihistamines or com-
bined intranasal fluticasone and azelastine are rapidly effective.43
d All recommended medications are considered safe at the usual dosage. First-generation oral H1-antihistamines are sedating
and should be avoided.44
d Oral or nebulized corticosteroids can be helpful in patients with severe disease whose symptoms are uncontrolled by other
treatment, although studies are lacking in patients with AR.45
d Further studies are needed in preschool children to make more firm recommendations possible, although recent studies show
the efficacy of oral H1-antihistamines.
46
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physical and emotional comfort, as well as in functional capacity
and quality of life (QOL). The control and severity of AR have
been defined in a similar manner to asthma.2,14,15Measures of AR
control include symptom scores, patients’ self-administered vi-
sual analog scales (VASs), objective measures of nasal obstruc-
tion, a recent modification of the Allergic Rhinitis and its
Impact on Asthma severity classification, and patients’ reported
outcomes, such as QOL or scores with several items.16,17 Howev-
er, the challenges of managing AR are increased by the fact that
patients do not often recognize their AR symptoms or confuse
themwith those of asthma.18 Therefore it is important for patients
to be able to use an AR symptom scoring system that is simple to
use and rapidly responsive to change.
As is the case for asthma, the best control of AR should be
achieved as early as possible to (1) improve patient satisfaction
and concordance to treatment and (2) reduce the consequences of
AR, including symptoms, reduced QOL, and school and work
absenteeism. Untreated AR can impair driving ability and put
patients at risk.19 The ultimate goal of AR control is to reduce the
costs incurred by AR.20-23
A step-up/step-down approach to AR pharmacotherapy based
on patient response might hold potential for optimal AR control
and cost of treatment.1 MASK has proposed that electronic daily
monitoring with VASs might help patients achieve optimal con-
trol of AR symptoms.2 Well-controlled AR is defined as a VAS
score of 2 or less of 10. VAS cutoff values to step up or down treat-
ment were proposed by comparison with pain VAS scores and
step-up schemes or from the literature in the field of allergy
(see the additional material in this article’s Online Repository at
www.jacionline.org).24-26RECOMMENDATIONS FOR THE TREATMENT OF
AR AND RHINOCONJUNCTIVITIS
The treatment of AR also requires the consideration of (1) the
type (rhinitis, conjunctivitis, and/or asthma) and severity ofsymptoms, (2) the relative efficacy of the treatment, (3) the speed
of onset of action of treatment, (4) current treatment, (5) historic
response to treatment, (6) patient’s preference, (7) interest to self-
manage, and (8) resource use. Guidelines27 and various state-
ments by experts for AR pharmacotherapy usually propose the
approach summarized in Box 1.28-46
Allergen immunotherapy appears to be as effective as phar-
macotherapy47,48 but is also regarded as a disease modifier inter-
vention with the potential of altering the natural history of allergic
diseases.49,50 Nonpharmacologic interventions, such as nasal fil-
ters51 or saline, have been found to be effective.PATIENTS’ VIEWS
Many patients with AR are not satisfied with their current
treatment,52-54 and this results in frequent nonadherence to ther-
apy.55,56 In some studies, most patients were satisfied with their
treatment, but full control was rarely achieved.54,57-59 Despite
the vast availability of treatment options, most patients are
‘‘very interested’’ in finding a new medication,56,60 and around
25% are ‘‘constantly’’ trying different medications to find one
that ‘‘works.’’56 Patients want more effective treatments that can
control all their symptoms, including ocular ones,61,62 and a
more rapid onset of action.63
Some patients believe that their health care provider does not
understand their allergy treatment needs or does not take their
allergy symptoms seriously.52 Many patients self-medicate with
over-the-counter drugs for a long period of time and usually
only consult a physician when their treatment is ineffective.58
In one study, patients chose a step-down therapy to speed up
the control of symptoms.64
A patient’s individual preference for an oral or intranasal route
treatment needs to be considered.52,64,65 In addition, health care
professionals need to inform the patient of the relative benefits
and harms of each prescribed treatment to support their decision
making.
Re-assess VAS daily up to 48-72 hr
VAS ≥ 5/10
Assessment of control in untreated symptomac paent
1st Line 
(An H1 oral/IN
or INCS or LTRA
or INCS+AZE*)
Iniate treatment
ANY 1st line
Iniate treatment
Intermient rhinis: ANY
Persistent rhinis: INCS  or INCS+AZE
VAS < 5/10
VAS ≥ 5/10VAS < 5/10
VAS ≥ 5/10
Consider referral to specicalist
and AIT
If symptomac: connue treatment
If no symptoms: consider step down 
treatment or STOP
VAS < 5/10
*: consider INCS+AZE if previous treatment ineﬀecve (historical)
Step up and Re-assess VAS daily up to 7-14 days
FIG 1. Step-up algorithm in untreated patients using the VAS (adolescents and adults). The proposed
algorithm considers the treatment steps and patient preference and VAS levels in ratio. If ocular symptoms
remain, add intraocular treatment.
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A step-up/step-down individualized approach to AR pharma-
cotherapy might hold the potential for optimal control of AR
symptoms while minimizing side effects and costs.1 However, the
following should be considered:
d as in asthmatic patients, treated and untreated patients
should be considered differently (Figs 1 and 2);
d most patients have received a previous treatment that
should guide health care professionals with regard to the
current prescription; and
d patterns of medication use in previously treated patients
should be evaluated when future treatment is initiated.
The step-up or step-down strategy should be discussed with the
patient and should consider the following:
d efficacy of previous treatments;
d adherence to treatment;
d the patient’s preference (route of administration, fear of
side effects, and experience of the patient regarding the
treatment);
d possible side effects or harms; and
d costs.
The step-up approach consists of the following:
d Step 1: For mild symptoms, use intranasal or oral nonsedat-
ing H1-antihistamines.
d Step 2: For moderate-to-severe symptoms and/or persistent
AR, use intranasal corticosteroids. The dose of some intra-
nasal corticosteroids can be increased according to the
package insert.
d Step 3: For patients with uncontrolled symptoms at step 2
(current or historical), use a combination of intranasalcorticosteroids and intranasal H1-antihistamines. However,
depending on the physicians’s experience, other therapeutic
strategies can be used.
d Step 4: It is possible that an additional short course of oral
steroids might help to establish control and continue con-
trol by step 3. Intraocular cromones or H1-antihistamines
can be added to improve the control of ocular symptoms.
d Treatment should be reassessed quickly (eg, 1-7 days) to
confirm control by using a step-up approach.
d Patients whose symptoms are uncontrolled at step 3 should
be considered as having severe chronic upper airway dis-
ease66,67 and might benefit from specialist referral and
assessment for allergy workup and nasal examination.68
For example, specialist referral should be considered if
there is failure to reduce the VAS score to less than 5 of
10 after 10 to 14 days, assuming the patient is adherent
to therapy.
d At all times, patient adherence and intranasal device tech-
nique mastery should be regarded as potential for lack of
treatment effect.
Alternatively, a step-down approach can be used, and step 3
treatment should be considered as the first option in patients with
a previous treatment failure or resistance to monotherapy. After a
few days of achieving complete control, consideration could be
given to treatment reduction. However, the step-down approach is
based on consensus, and more data are needed.
The duration of treatment is determined by the type of rhinitis
(intermittent or persistent). In the patient with intermittent
rhinitis, treatment should be continued daily for 2 weeks or for
the duration of the pollen season or other specific allergen
exposure. In the patient with persistent rhinitis, a longer course
Re-assess VAS daily up to 48-72 hr
If symptomac: connue treatment
If no symptoms: consider step down 
treatment
VAS < 5/10
1st Line 
(An H1 O/IN or INCS 
Or LTRA or  INCS+AZE)
VAS ≥ 5/10
Step-up treatment
INCS or INCS+AZE
Persistent rhinis
or allergen exposure
Maintain or step up
treatment
VAS ≥ 5/10
VAS < 5/10
Intermient rhinis
No allergen exposure
Step-down treatment
or STOP
Re-assess VAS daily up to D7
Step up and 
Re-assess VAS daily
VAS ≥ 5/10
Assessment of control in treated symptomac paent
VAS < 5/10
Consider referral to specicalist
and AIT
FIG 2. Step-up algorithm in treated patients using the VAS (adolescents and adults). The proposed
algorithm considers the treatment steps and patient preference and VAS levels in ratio. If ocular symptoms
remain, add intraocular treatment.
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concordance with agreed regimens because treatment failure can
be a result of poor patient concordance.
CONCLUSION
We propose a simple algorithm to step up or step down AR
treatment globally. However, its use varies depending on the
availability of medications in different countries and depending
on resources. These issues have not been approached in the
present article because of their variability between countries.
Inherently, algorithms are a combination of individual decision
nodes that represent separate recommendations. They require
testing as a complete algorithm and comparison with alternative
strategies to explore whether the combination of these separate
recommendations leads to more benefit than harm when applied
in practice. Thus this algorithm, as with other algorithms, requires
testing in large-scale trials to provide the necessary certainty in
available evidence. The current algorithm is being developed by
MASK2 for a CDSS that will be available on Apple and Android
and that will provide opportunities for evaluation.
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Certain differences between groups in their VAS scores or
changes in scores might have no clinical relevance, even if they
achieve statistical significance. A wide range of minimal clini-
cally important differences (MCIDs) in change scores on the pain
VAS have been reportedE1 by using different methods. MCDIs
ranged from 9 to 30 mm (of 100 mm) in emergency
departments.E2-E6 In other settings, changes of 33%E7 and
31 mmE8 have been shown to be clinically meaningful. In patients
with endometriosis, the pain MCID was set at 10 mm.E9 The
MCID for the fatigue VAS was around 10 mm in a large rheuma-
toid arthritis clinical practice and similar to that seen in clinical
trials.E10 The MCID in the VAS pain score does not differ with
sex, age, and cause-of-pain groupsE3 or with the severity of
pain being experienced.E11 However, the linearity of the pain
VAS is found in someE12 but not allE1,E13,E14 studies. Pain VAS
measurement error has been reported to be up to 20 mm.E15,E16
Consequently, change scores and the calculations of aspects,
such as MCIDs, can be carefully considered by the potential
lack of interval scaling of the VAS and further compromised by
the magnitude of measurement error. Repeated pain VAS data
meet the strict requirements of the Rasch model, including unidi-
mensionality, and they were internally valid.E1 However, the pain
VAS does not behave linearly, and the MCID can underestimate
or overestimate true change during repeated pain VAS.E17
In patients with AR, to our knowledge, there is a single study
that has estimated MCDIs in the VAS during treatment.E18 By us-
ing receiver operating characteristic curve analysis, an appro-
priate method for estimation of MCDIs, the established cutoff
variation of 23 mm for the VAS was associated with a cutoff vari-
ation of 0.5 for the Rhinoconjunctivitis Quality of Life Question-
naire (RQLQ). Sensitivity analysis with RQLQ and Total
SymptomScore 6 scales confirmed the aptitude of the cutoff value
(23 mm) to discriminate changes in symptoms and QOL. The
MCID was the same whatever the baseline VAS level.E18
A level of more than 23 mm appears to be a relevant cutoff.
VAS changes appear to encompass both symptoms and disease-
specific QOL.E18,E19 Another study, the Control of Allergic
Rhinitis and Asthma Test,E20,E21 approximated the VAS MCDI.
In CARAT, the MCID is 4 (range, 0-30).E22 The real-life study
of Demoly et alE18 in primary care used the same methods as a
cluster randomized trial carried out in specialist practices.E23
Both studies, which were carried out in France in large popula-
tions, showed a very similar change in VAS levels during treat-
ment depending on total symptom scores and RQLQ sores.
These studies suggest that the cutoff of 23 mmE18 is appropriate
to find a clinically significant difference.
VAS levels appear to be similar in different countries in patients
with severe intermittent or persistent rhinitis. AVAScan be used in
all age groups, including preschool children (guardian evalua-
tion)E24 and the elderly.E25 Furthermore, it can be used in a wide
variety of languages.E25-E32 VAS levels vary with the Allergic
Rhinitis and its Impact on Asthma classification in many langua-
ges.E28,E33-E35 A VAS level of 50 (>100 mm) is suggestive of
moderate-to-severe AR,E19,E36,E37 although in some studies the
cutoffwas greater than 60mm.E29AVASwas used to define severe
chronic upper airway disease.E23 Thus the MCDI found in 2 large
French populations can be generalized to other countries with
different languages and cultures across the lifecycle. However,
future studies should refine this cutoff level.
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